Advertisement

Pruritus pp 389-392 | Cite as

Opioid Receptor Antagonists or Agonists

  • Laurent MiseryEmail author
Chapter

Abstract

Opioids have three receptors in primates: mu (MOR), kappa (KOR) and delta (DOR). Systemic administration of mu agonists produce scratching but kappa agonist or delta agonists do not evoke scratching. Kappa agonists are able to inhibit opioid-induced itch by preventing or reversing it, as well as mu antagonists. As a mu-antagnist, naltrexone is the most commonly used but others could be effective: naoloxone, nalbuphine, nalmefene and butorphanol. The kappa-agonist nalfurafine is approved in Japan for the treatment of itch.

Keywords

Opioid Kappa receptor Mu receptor 

References

  1. 1.
    Ko MC, Song MS, Edwards T, Lee H, Naughton NN. The role of central mu opioid receptors in opioid-induced itch in primates. J Pharmacol Exp Ther. 2004;310:169–76.CrossRefPubMedGoogle Scholar
  2. 2.
    Ko MC, Lee H, Song MS, Sobczyk-Kojiro K, Mosberg HI, Kishioka S, et al. Activation of kappa-opioid receptors inhibits pruritus evoked by subcutaneous or intrathecal administration of morphine in monkeys. J Pharmacol Exp Ther. 2003;305:173–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Ständer S, Weisshaar E, Luger T. Neurophysiological and neurochemical basis of modern pruritus treatment. Exp Dermatol. 2008;17:161–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Bigliardi-Qi M, Lipp B, Sumanovski LT, Buechner SA, Bigliardi PL. Changes of epidermal mu-opiate receptor expression and nerve endings in chronic atopic dermatitis. Dermatol (Basel, Switzerland). 2005;210:91–9.CrossRefGoogle Scholar
  5. 5.
    Bigliardi-Qi M, Gaveriaux-Ruff C, Pfaltz K, Bady P, Baumann T, Rufli T, et al. Deletion of mu- and kappa-opioid receptors in mice changes epidermal hypertrophy, density of peripheral nerve endings, and itch behavior. J Invest Dermatol. 2007;127(6):1479–88.CrossRefPubMedGoogle Scholar
  6. 6.
    Tominaga M, Ogawa H, Takamori K. Possible roles of epidermal opioid systems in pruritus of atopic dermatitis. J Invest Dermatol. 2007;127(9):2228–35.CrossRefPubMedGoogle Scholar
  7. 7.
    Phan NQ, Lotts T, Antal A, Bernhard JD, Ständer S. Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a literature review. Acta Derm Venereol. 2012;92:555–60.CrossRefPubMedGoogle Scholar
  8. 8.
    Kjellberg F, Tramer MR. Pharmacological control of opioid-induced pruritus: a quantitative systematic review of randomized trials. Eur J Anaesthesiol. 2001;18(6):346–57.CrossRefPubMedGoogle Scholar
  9. 9.
    Metze D, Reimann S, Beissert S, Luger T. Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases. J Am Acad Dermatol. 1999;41(4):533–9.PubMedGoogle Scholar
  10. 10.
    Wolfhagen FH, Sternieri E, Hop WC, Vitale G, Bertolotti M, Van Buuren HR. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology. 1997;113(4):1264–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Peer G, Kivity S, Agami O. Randomized cross-over trial of naltrexone in uremic pruritus. Lancet. 1996;348:1552–4.CrossRefPubMedGoogle Scholar
  12. 12.
    Pauli-Magnus C, Mikus G, Alscher D, Kirschner T, Nagel W, Gugeler N, et al. Naltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study. J Am Soc Nephrol. 2000;11:514–9.PubMedGoogle Scholar
  13. 13.
    Legroux-Crespel E, Cledes J, Misery L. A comparative study on the effects of naltrexone and loratadine on uremic pruritus. Dermatol (Basel, Switzerland). 2004;208(4):326–30.CrossRefGoogle Scholar
  14. 14.
    Heyer G, Groene D, Martus P. Efficacy of naltrexone on acetylcholine-induced alloknesis in atopic eczema. Exp Dermatol. 2002;11(5):448–55.CrossRefPubMedGoogle Scholar
  15. 15.
    Ajayi A, Kolawole B, Udoh S. Endogenous opioids, mu-opiate receptors and chloroquine-induced pruritus: a double-blind comparison of naletrexone and promethazine in patients with malaria fever who have an established history of generalized chloroquine-induced pruritus. Int J Dermatol. 2004;43:972–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Dawn AG, Yosipovitch G. Butorphanol for treatment of intractable pruritus. J Am Acad Dermatol. 2006;54(3):527–31.CrossRefPubMedGoogle Scholar
  17. 17.
    Wakasa Y, Fujiwara A, Umeuchi H, Endoh T, Okano K, Tanaka T, et al. Inhibitory effects of TRK-820 on systemic skin scratching induced by morphine in rhesus monkeys. Life Sci. 2004;75(24):2947–57.CrossRefPubMedGoogle Scholar
  18. 18.
    Togashi Y, Umeuchi H, Okano K, Ando N, Yoshizawa Y, Honda T, et al. Antipruritic activity of the kappa-opioid receptor agonist, TRK-820. Eur J Pharmacol. 2002;435(2–3):259–64.CrossRefPubMedGoogle Scholar
  19. 19.
    Wikstrom B, Gellert R, Ladefoged SD, Danda Y, Akai M, Ide K, et al. Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies. J Am Soc Nephrol. 2005;16(12):3742–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Kumagai H, Ebata T, Takamori K, Muramatsu T, Nakamoto H, Suzuki H. Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a phase III, randomized, double-blind, placebo-controlled study. Nephrol Dial Transplant. 2010;25:1251–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Kumagai H, Ebata T, Takamori K, Miyasato K, Muramatsu T, Nakamoto H, et al. Efficacy and safety of a novel κ-agonist for managing intractable pruritus in dialysis patients. Am J Nephrol. 2012;36:175–83.CrossRefPubMedGoogle Scholar
  22. 22.
    Inui S. Nalfurafine hydrochloride to treat pruritus: a review. Clin Cosmet Investig Dermatol. 2015;8:249–55.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Ständer S, Weisshaar E, Raap U. Emerging drugs for the treatment of pruritus. Expert Opin Emerg Drugs. 2015;20:515–21.Google Scholar
  24. 24.
    Lee IH, Lee IO. The antipruritic and antiemetic effects of epidural droperidol: a study of three methods of administration. Anesth Analg. 2007;105:251–5.CrossRefPubMedGoogle Scholar
  25. 25.
    Bigliardi PL, Stammer H, Jost G, Rufli T, Buchner S, Bigliardi-Qi M. Treatment of pruritus with topically applied opiate receptor antagonist. J Am Acad Dermatol. 2007;56(6):979–88.CrossRefPubMedGoogle Scholar
  26. 26.
    Lim GJ, Ishiuji Y, Dawn A, Harrison B, do Kim W, Atala A, et al. In vitro and in vivo characterization of a novel liposomal butorphanol formulation for treatment of pruritus. Acta Derm Venereol. 2008;88(4):327–30.PubMedGoogle Scholar
  27. 27.
    Herzog JL, Solomon JA, Draelos Z, Fleischer A, Stough D, Wolf DI, et al. A randomized, double-blind, vehicle-controlled crossover study to determine the anti-pruritic efficacy, safety and local dermal tolerability of a topical formulation (srd174 cream) of the long-acting opiod antagonist nalmefene in subjects with atopic dermatitis. J Drugs Dermatol. 2011;10:853–60.PubMedGoogle Scholar

Copyright information

© Springer-Verlag London 2016

Authors and Affiliations

  1. 1.Laboratory of Neurosciences of Brest, and Department of DermatologyUniversity Hospital, and University of BrestBrestFrance

Personalised recommendations